Latest Leadership News

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

CVC Limited posted a net profit after tax of $7.7 million for FY2026, underpinned by a $37.8 million profit from the Laverton sale and a $13.3 million impairment from the Liverpool project. The company paid a special dividend and restructured leadership amid ongoing capital management efforts.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

North Stawell Minerals (ASX:NSM) sharpens its focus on replicating the multi-million ounce Stawell Gold Mine, unveiling an 87,300-ounce Wildwood resource and a pipeline of high-grade targets along the Darlington-Caledonia trend in Victoria.

AIX has acquired an 8% holding in AI powerhouse Databricks during its US$5 billion funding round, marking a significant expansion in the trust’s AI-focused portfolio.

humm Group reports a 60% drop in FY26 net profit after tax to $15.7 million, weighed down by irregular legal expenses and credit impairments, while declaring a final dividend and completing major board renewal.

HighCom Limited’s FY26 results reveal a sharp revenue drop and widening loss driven by a US Government shutdown, but a strengthened leadership team and expanded global sales pipeline set the stage for recovery.

Peet Limited delivered a record FY26 with net profit after tax soaring 77% to $103.4 million, driven by robust sales and a 39% jump in contracts on hand. The company boosted dividends by 68%, reflecting confidence in its diverse masterplanned communities pipeline.

Integral Diagnostics (ASX: IDX) delivered a robust FY26 with 26% revenue growth to $788.6 million, a 677% surge in profit after tax to $22 million, and a 50% hike in its final dividend to 6 cents per share.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.